SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will present updates on several key innovations in whole-genome sequencing, proteomics, and single-cell technology at the American Society of Human Genetics (ASHG) Annual Meeting next week in Denver. The latest details will be presented alongside new data from key opinion leaders in next-generation sequencing (NGS), illustrating the potential impact of Illumina's emerging innovations.
First-of-its-kind technology streamlines whole-genome workflows, expands genomic insights
In a mainstage presentation on November 6, Steve Barnard, PhD, chief technology officer, will reveal new details on the company's constellation mapped read technology, originally announced in the company's August 2024 strategy update as the "comprehensive genome." Currently under development, this novel technology is designed to streamline whole-genome workflows and eliminate traditional library prep.
Additionally, constellation mapped read technology will deliver Illumina's most comprehensive whole genome yet, adding long-range information to Illumina's proven, highly accurate XLEAP-SBS™ chemistry. The expanded insights from this proprietary technology will resolve challenging genic regions, such as pseudogenes, while generating ultra-long phased data and providing a high-resolution view of complex structural variation.
"These are unprecedented, breakthrough technologies that will power our future comprehensive whole-genome solutions," Barnard said. "We believe this solution could be the de facto genome of the future, offering expanded information and simplicity for labs."
Barnard will be joined on stage by Niall Lennon, PhD, chair and chief scientific officer of Broad Clinical Labs, who will present early data on the flexibility and capabilities of the technology.
The first product based on constellation mapped read technology is set to begin early access in the first half of 2025.
Illumina Protein Prep: A complete NGS-based proteomics solution
On November 7, Illumina will present updates on its proteomics solution, Illumina Protein Prep, which delivers sample-to-analysis protein discovery. The solution is an outcome of Illumina's partnership with Standard BioTools (formerly SomaLogic), announced in 2022.
Proteomics enables the observation of direct cellular function to gain insights on protein-driven disease traits, and the inclusion of proteomics in Illumina's NGS portfolio provides visibility into the entire biological process. The presentation will highlight the early access solution's ability to identify and quantify more than 6000 human proteins and its readout compatibility with NovaSeq™ X and NovaSeq 6000 Systems to enable multiomics on a single platform—a key differentiator from existing proteomics methodologies.
Kamel Lahouel, PhD, assistant professor in the Early Detection and Prevention Division at The Translational Genomics Research Institute (TGen), part of City of Hope, will present on a new pilot study using Illumina Protein Prep to investigate the potential of circulating protein concentrations as biomarkers for cancer detection. TGen is part of an early access, limited release program for the solution with select customers.
When it launches in early 2025, Illumina Protein Prep will feature 9000 unique human proteins.
Leading single-cell technology: Fluent PIPseq™ V
On November 7, Illumina will showcase PIPseq V, a single-cell analysis solution currently on the market from Fluent BioSciences, an Illumina company. In a collaborative talk, experts will discuss how PIPseq V enables researchers to delve deeper into the complexities of cell biology with a scalable, accessible solution. Presenters will share early access data and insights from a large study on more than 1 million neuronal single cells using PIPseq V.
Additional updates
Barnard's presentation on November 6 will also cover the latest updates on 25B 100-cycle and 200-cycle kits for the NovaSeq X Series, which will be available by end of year. The kits will be a key enabler of multiomics, allowing customers to perform single-cell, proteomics, and other applications at scale.
"We look forward to expanding on these innovations with our customers and peers at ASHG," Barnard said. "We also look forward to sharing our latest instruments, the MiSeq™ i100 Series, with our fellow NGS enthusiasts at our booth."
Illumina's new MiSeq i100 Series will be on display at booth 503 during the meeting, and Illumina will be presenting scientific findings in five poster presentations and abstracts.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Christine Douglass
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$144.14 |
| Daily Change: | -3.52 -2.38 |
| Daily Volume: | 1,494,245 |
| Market Cap: | US$22.960B |
October 09, 2024 August 27, 2024 July 18, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
